UBS Asset Management Americas Inc. Sells 8,692 Shares of Global Blood Therapeutics, Inc. (GBT)

UBS Asset Management Americas Inc. lessened its stake in Global Blood Therapeutics, Inc. (NASDAQ:GBT) by 53.7% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 7,500 shares of the company’s stock after selling 8,692 shares during the period. UBS Asset Management Americas Inc.’s holdings in Global Blood Therapeutics were worth $205,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. BlackRock Inc. lifted its stake in shares of Global Blood Therapeutics by 30.0% in the 2nd quarter. BlackRock Inc. now owns 3,404,538 shares of the company’s stock valued at $93,114,000 after acquiring an additional 785,691 shares during the last quarter. Vanguard Group Inc. lifted its stake in shares of Global Blood Therapeutics by 40.1% in the 1st quarter. Vanguard Group Inc. now owns 2,535,980 shares of the company’s stock valued at $93,451,000 after acquiring an additional 726,366 shares during the last quarter. State Street Corp lifted its stake in shares of Global Blood Therapeutics by 132.0% in the 1st quarter. State Street Corp now owns 672,728 shares of the company’s stock valued at $24,788,000 after acquiring an additional 382,744 shares during the last quarter. Morgan Stanley lifted its stake in shares of Global Blood Therapeutics by 140.0% in the 1st quarter. Morgan Stanley now owns 334,872 shares of the company’s stock valued at $12,340,000 after acquiring an additional 195,323 shares during the last quarter. Finally, Fernwood Investment Management LLC lifted its stake in shares of Global Blood Therapeutics by 7.2% in the 2nd quarter. Fernwood Investment Management LLC now owns 281,457 shares of the company’s stock valued at $7,698,000 after acquiring an additional 18,947 shares during the last quarter. 86.19% of the stock is owned by institutional investors.

In related news, Director Charles J. Homcy sold 70,000 shares of the company’s stock in a transaction that occurred on Friday, October 27th. The stock was sold at an average price of $33.97, for a total value of $2,377,900.00. Following the sale, the director now owns 83,328 shares in the company, valued at approximately $2,830,652.16. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, VP Peter Radovich sold 12,500 shares of the company’s stock in a transaction that occurred on Monday, October 30th. The stock was sold at an average price of $35.00, for a total value of $437,500.00. Following the completion of the sale, the vice president now owns 2,684 shares in the company, valued at approximately $93,940. The disclosure for this sale can be found here. Insiders have sold a total of 91,500 shares of company stock worth $3,093,350 in the last quarter. Company insiders own 5.30% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This article was first published by Community Financial News and is the sole property of of Community Financial News. If you are viewing this article on another domain, it was illegally stolen and reposted in violation of international copyright laws. The original version of this article can be accessed at https://www.com-unik.info/2017/11/06/ubs-asset-management-americas-inc-sells-8692-shares-of-global-blood-therapeutics-inc-gbt.html.

Global Blood Therapeutics, Inc. (NASDAQ:GBT) opened at $41.55 on Monday. Global Blood Therapeutics, Inc. has a twelve month low of $13.35 and a twelve month high of $43.95.

Global Blood Therapeutics (NASDAQ:GBT) last posted its earnings results on Thursday, November 2nd. The company reported ($0.66) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.04). During the same period in the previous year, the firm posted ($0.58) earnings per share. research analysts predict that Global Blood Therapeutics, Inc. will post -2.42 EPS for the current year.

A number of research analysts recently issued reports on GBT shares. BidaskClub upgraded Global Blood Therapeutics from a “hold” rating to a “buy” rating in a report on Wednesday, November 1st. Cowen and Company restated an “outperform” rating and set a $83.00 price target on shares of Global Blood Therapeutics in a report on Monday, August 14th. Needham & Company LLC set a $51.00 price target on Global Blood Therapeutics and gave the company a “buy” rating in a report on Tuesday, October 24th. J P Morgan Chase & Co restated an “overweight” rating and set a $46.00 price target (up previously from $44.00) on shares of Global Blood Therapeutics in a report on Tuesday, August 8th. Finally, Oppenheimer Holdings, Inc. set a $53.00 price target on Global Blood Therapeutics and gave the company a “buy” rating in a report on Monday, October 23rd. Two research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. The company presently has an average rating of “Buy” and an average price target of $54.08.

Global Blood Therapeutics Profile

Global Blood Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering, developing and commercializing therapeutics to treat blood-based disorders. The Company is developing its initial product candidate, GBT440, as an oral, once-daily therapy for sickle cell disease (SCD).

Institutional Ownership by Quarter for Global Blood Therapeutics (NASDAQ:GBT)

What are top analysts saying about Global Blood Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Global Blood Therapeutics Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit